Gene Expression Model Predicts Hepatitis C Treatment Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current peginterferon plus ribavirin therapy for hepatitis C has suboptimal sustained virologic response rates and adverse effects, with limited predictive tools for treatment outcomes, particularly for HCV genotype 1 patients.
Innovation Solution
A genetic model using the expression profiles of RSAD2, LOC26010, HERC5, HERC6, IFI44, SERPING1, IFITM3, and DDX60 genes in peripheral blood mononuclear cells after one week of treatment to predict treatment response, providing a scoring method that identifies responders and non-responders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peginterferon plus ribavirin therapy is used to treat HCV genotype 1, then treatment coverage is maintained, but sustained virologic response rate is suboptimal (40%-70%)
Solution Approach 1:
The patent measures gene expression levels of interferon-stimulated genes (ISGs) at baseline (before treatment starts) to predict which patients will respond to peginterferon plus ribavirin therapy. This preliminary assessment allows clinicians to identify responders and non-responders before committing to the full treatment course, enabling early stratification and adjustment of treatment strategies for HCV genotype 1 patients.
2Reliability
If treatment duration is extended to 48 weeks to improve SVR rate, then response rate increases, but adverse effects become intolerable
Solution Approach 1:
By measuring ISG expression levels at baseline, the patent enables early identification of patients who are unlikely to respond to therapy. This allows clinicians to avoid subjecting non-responders to prolonged 48-week treatment with intolerable adverse effects, and instead redirect them to alternative therapies such as direct-acting antivirals, thereby reducing unnecessary harm while maintaining optimal response rates for actual responders.
Solution Approach 2:
The patent uses baseline gene expression profiles as a predictive feedback mechanism to guide treatment decisions. By assessing ISG expression levels before treatment, the system provides feedback on expected treatment outcome, allowing for personalized treatment duration and strategy adjustments that balance efficacy with minimization of adverse effects.
3Reliability
If direct acting antiviral agents are used, then sustained virologic response rate improves to 90%, but treatment cost becomes prohibitive
Solution Approach 1:
The patent employs baseline ISG expression profiling to predict treatment response to peginterferon plus ribavirin therapy at low cost. This preliminary prediction allows clinicians to identify patients who will respond well to the inexpensive pegIFN/ribavirin regimen, avoiding the need to prescribe expensive direct-acting antivirals to patients who would respond adequately to cheaper therapy, thereby optimizing resource allocation while maintaining high response rates.
Solution Approach 2:
The patent utilizes a cost-effective baseline gene expression assessment (using readily available ISG markers) as a disposable screening tool to guide treatment selection. This inexpensive predictive test enables differentiation between patients who need expensive DAAs and those who can be effectively treated with cheaper peginterferon plus ribavirin, making cost-effective treatment decisions without sacrificing efficacy for responsive patients.
4Loss of information
If traditional predictors (viral load, IL28B genotype) are used, then treatment guidance is provided, but prediction accuracy is insufficient
Solution Approach 1:
The patent combines multiple interferon-stimulated gene expression levels (ISGX1, ISGY1, ISG15, OAS1, IFITM3, MX1) into a composite predictive model. This composite approach integrates information from multiple genes involved in the interferon signaling pathway, providing a more comprehensive and accurate prediction of treatment response to peginterferon plus ribavirin therapy compared to single-marker predictors like IL28B genotype or viral load alone.
Solution Approach 2:
The patent shifts from using traditional static predictors (viral load, IL28B genotype) to measuring dynamic gene expression levels of interferon-stimulated genes at baseline. This parameter change captures the functional response of the patient's immune system to interferon stimulation, providing more relevant and accurate predictive information about treatment outcome than traditional demographic or virologic parameters.
Data Source
AI summary
The present invention provides a method for predicting treatment efficacy of peginterferon plus ribavirin treatment in a subject suffering from chronic hepatitis C comprising: (a) measuring gene expression levels of genes comprising RSAD2, LOC26010, HERC5, HERC6, IFI44, SERPING1, IFITM3 and DDX60 of a blood sample from the subject after one week of the peginterferon plus ribavirin treatment; and (b) calculating a gene score according to cumulative fold change of the gene expression levels, when the gene score is equal to or higher than a cut-off value, the method predicts successful treatment of chronic hepatitis C with the peginterferon plus ribavirin treatment for the subject.